Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts

Karun Neupane, Zahoor Ahmed, Hira Pervez, Rabia Ashraf, Aneela Majeed, Karun Neupane, Zahoor Ahmed, Hira Pervez, Rabia Ashraf, Aneela Majeed

Abstract

Coronavirus disease-2019 (COVID-19), first reported in China during December of 2019, is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection later spread very rapidly around the globe with over 8,708,008 cases reported, including more than 461,715 deaths reported across at least 216 countries by June 20, 2020. It was declared as a global pandemic by the World Health Organization (WHO) on March 11, 2020. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatment. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab. We have tabulated available data on various clinical trials testing various aspects of COVID-19 therapeutics.

Keywords: coronavirus; covid-19; hydroxychloroquine; remdesivir; sars-cov-2; therapeutics; treatment.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2020, Neupane et al.

References

    1. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China] Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145.
    1. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19) Zhang Y, Chen C, Zhu S, et al. China CDC Weekly. 2020;2:123–124.
    1. Q&A: The novel coronavirus outbreak causing COVID-19. Fisher D, Heymann D. BMC Medicine. 2020;18:1–3.
    1. Marco C, Michael R, Arturo C, et al. Treasure Island: StatPearls [Internet]. StatPearls Publishing; 2020. Features, Evaluation and Treatment Coronavirus (COVID-19)
    1. Gilead’s Investigational Antiviral Remdesivir Receives U.S. [Jun;2020 ]; 2020
    1. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. Adedeji AO, Severson W, Jonsson C, et al. J Virol. 2013;87:8017–8028.
    1. Anti-SARS coronavirus agents: a patent review (2008-present) Kumar Kumar, V. V., Jung Jung, Y. S. and Liang, P. H. Expert Opin Ther Pat. 2013;23:1337–1348.
    1. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Wang M, Cao R, Zhang L, et al. Cell Res. 2020;30:269–271.
    1. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. de Wit E, Feldmann F, Cronin J, et al. Proc Natl Acad Sci U S A. 2020;117:6771–6776.
    1. Compassionate use of remdesivir for patients with severe Covid-19. Grein J, Ohmagari N, Shin D, et al. N Engl J Med. 2020;382:2327–2336.
    1. (NIAID) NIoAaID. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. [Jun;2020 ]; 2020
    1. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Kujawski SA, Wong KK, Collins JP, et al. medRxiv. 2020
    1. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Sheahan TP, Sims AC, Leist SR, et al. Nat Commun. 2020;11:222.
    1. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. Cao B, Wang Y, Wen D, et al. N Engl J Med. 2020;382:1787–1799.
    1. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. Liu C, Zhou Q, Li Y, et al. ACS Cent Sci. 2020;6:315–331.
    1. More than 80 clinical trials launch to test coronavirus treatments. Maxmen Maxmen, A A. Nature. 2020;578:347.
    1. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Kadam RU, Wilson IA. Proc Natl Acad Sci U S A. 2017;114:206–214.
    1. Dexamethasone reduces death in hospitalized patients with severe respiratory complications of COVID-19. [Jun;2020 ]; 2020
    1. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Richardson P, Griffin I, Tucker C, et al. Lancet. 2020;395:30–31.
    1. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Lundberg L, Pinkham C, Baer A, et al. Antiviral Res. 2013;100:662–672.
    1. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Caly L, Druce JD, Catton MG, et al. Antiviral Res. 2020:104787.
    1. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Corman VM, Landt O, Kaiser M, et al. Euro Surveill. 2020;25:2000045.
    1. Effective treatment of severe COVID-19 patients with tocilizumab. Xu X, Han M, Li T, et al. Proc Natl Acad Sci U S A. 2020;117:10970–10975.
    1. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. J Infect Dis. 2015;211:80–90.
    1. A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019. Chen Q, Quan B, Li X, et al. J Med Virol. 2020
    1. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Cao W, Liu X, Bai T, et al. Open Forum Infect Dis. 2020;7:0.
    1. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Gurwitz D. Drug Dev Res. 2020
    1. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Fang L, Karakiulakis G, Roth M. Lancet Respir Med. 2020;8:0.
    1. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Russell B, Moss C, Rigg A, et al. Ecancermedicalscience. 2020;14:1023.
    1. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. Wang H, Ding Y, Li X, et al. N Engl J Med. 2003;349:507–508.
    1. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. Lee N, Chan KA, Hui DS, et al. J Clin Virol. 2004;31:304–309.
    1. Hydroxychloroquine and azithromycin as a treatment of COVID- 19: results of an open-label non-randomized clinical trial. Gautret P, Lagier J-C, Parola P, et al. Int J Antimicrob Agents. 2020:105949.
    1. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Raoult D, Houpikian P, Dupont HT, et al. Arch Intern Med. 1999;159:167–173.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit